Search
Finasteride
go.drugbank.com/drugs/DB01216ApprovedInvestigationalCompared to alpha-blockers that focus on providing the rapid relief of symptoms, 5α-reductase inhibitors aim to target the underlying disease by blocking the effects of the primary androgen involved in … [L6244,L10565] In 1998, it was approved by the FDA to treat male pattern hair loss.
Filgrastim
go.drugbank.com/drugs/DB00099ApprovedInvestigationalFilgrastim mimics the biological actions of G-CSF to increase the levels of neutrophils in the blood. … [L40773] A long-acting, pegylated G-CSF, [pegfilgrastim], was made available to increase the duration of action of the drug.
Products: E/0.5ML, E/0.5MLElagolix
go.drugbank.com/drugs/DB11979ApprovedInvestigationalAs of 24 July 2018, however, the U.S. … Moreover, women who are affected by this condition can suffer for up to six to ten years and visit multiple physicians before receiving a proper diagnosis [A35868, A35869, F801].
Categories: Gonadotropin Releasing Hormone Receptor AntagonistsTechnetium Tc-99m nofetumomab merpentan
go.drugbank.com/drugs/DB09336ApprovedWithdrawnTechnetium Tc-99m nofetumomab merpentan (Tc-99m nm) consists of a Fab fragment of an IgG2b of the pancarcinoma murine antibody NR-LU-10. … It was after discontinued on August 13, 2013, but in the 2018 FDA submission list, it can be found as a substance type II (Drug substance) with an active status.[L1650, L1082]
Synonyms: Technetium Tc 99m nofetumomab merpentan, Technetium Tc-99m nofetumomab merpentanBezitramide
go.drugbank.com/drugs/DB01459ApprovedIllicitWithdrawnAfter cases of fatal overdose in the Netherlands in 2004 the drug was withdrawn from the market. Bezitramide has never been FDA approved and is currently a schedule II drug. … Bezitramide is a narcotic analgesic which was discovered in 1961, clinically tested around the 1970's [A14383], and marketed under the name Burgodin.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeDiphenoxylate
go.drugbank.com/drugs/DB01081ApprovedIllicitInvestigationalThis medication is classified as a Schedule V under the Controlled Substances Act by the Food and Drug Administration (FDA) and the DEA in the United States when used in preparations.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeAminopterin
go.drugbank.com/drugs/DB08878ApprovedWithdrawnClinicians need to be aware of the characteristic teratologic effects of aminopterin and methotrexate. … In the 1950's its production was discontinued in favor of methotrexate, which is less potent but less toxic. Off label, aminopterin has also been used in the treatment of psoriasis.
Cocaine
go.drugbank.com/drugs/DB00907ApprovedIllicitInvestigationalIt also has powerful central nervous system effects similar to the amphetamines and is a drug of abuse. … An alkaloid ester extracted from the leaves of plants including coca.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromePhenazopyridine
go.drugbank.com/drugs/DB01438ApprovedInvestigationalIn the USA, this drug was previously marked by Roche but has been discontinued by the FDA.[L7832] It is still used in various parts of the world. … Ingestion of phenazopyridine is found to change the appearance of the urine by imparting an orange or red color, as it is considered an azo dye.[L7829]
Dihydroergocornine
go.drugbank.com/drugs/DB11273Approved[A32964] The formation of dihydroergocornine implies the hydrogenation of the double bonds in the lysergic acid. … [T190] It is found as one of the components in the ergoloid mesylate mixture. To know more about this mixture please refer to [DB01049]
Categories: Ergot-derivative Dopamine Receptor Agonists